The cottontail rabbit papillomavirus (CRPV)/rabbit model has proven to be the most versatile preclinical model to test antiviral, immunopotentiating and immunotherapeutic strategies for papilloma-virus infections. We have utilized this model for many years and have recently observed significant improvements in the utility of the model. Improvements have included various techniques to infect rabbit skin sites with strains of wild-type and mutant CRPV DNA prepared using standard molecular biological procedures. A better understanding of the virus life cycle in vivo has been gained also from these studies such that we now have several defined strains of CRPV including i) antigenically diverse strains of CRPV, ii) mutant strains of CRPV with reduced growth rates, and iii) mutant strains of CRPV that demonstrate accelerated malignant progression rates. Collectively, these mutant genomes provide laboratories with a powerful pre-clinical model to assess a variety of antiviral therapies. Many of the treatments already tested in the CRPV/rabbit model have shown parallel efficacy against HPV infections in a clinical setting. Some of our recent experiences with the CRPV/rabbit model are outlined in this brief overview.
Introduction
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Papillomaviruses infect epithelial tissues of cutaneous and mucosal origin and are ubiquitous throughout the animal kingdom from reptiles to primates (Howley & Lowy, 2001; zur Hausen, 2002) . In humans, more than 100 human papillomavirus (HPV) types have been defined genetically, with approximately 15-20 types associated with various cutaneous and mucosal cancers, notably cervical cancer (Munoz et al., 2003) . Current antiviral treatments utilize ablative procedures that are designed to remove and/or destroy existing lesions. However, these procedures treat only visible infections and achieve a modest success rate due to the confounding outcome of recurrences (Auborn & Carter, 2000; Beutner et al., 1998) . Once HPV infections of the cervix reach the stage of invasive carcinoma with corresponding metastasis, the prognosis for patient survival is poor and traditional treatments using radiation and chemotherapy are largely unsuccessful. A secondary aspect of treatment failure is the potential outcome of undetected secondary and subclinical infections that may contribute to disease persistence and recurrence.
Given these treatment failures, there is a need for predictive pre-clinical models to test existing and new treatment modalities and to establish efficacy and safety of any new antiviral product. An important secondary goal is the need for an immunocompetent host/papillomavirus model to test the effectiveness of prophylactic and therapeutic vaccines, as well as to measure the antiviral impact of various immunomodulatory compounds and/or strategies.
Current pre-clinical models to test papillomavirus therapeutic strategies are limited by the extreme tissue and species restriction of the Papillomaviridae. In addition, there is a complete lack of small rodent laboratory models for natural and experimental infection with species-specific rodent papillomaviruses. The only in vivo pre-clinical models that support antiviral testing against HPV infections utilize human tissue xenografts and immunocompromised mice (Kreider et al., 1986; Bonnez et al., 1993) . Both human (HPV6, HPV11, HPV16, HPV40, HPV83) and animal (BPV, CRPV) papillomas can be grown in these mice by matching the infectious virus stock with epithelial tissues from the natural virus host (Kreider et al., 1986; Bonnez et al., 1998; Christensen and Kreider, 1990; Christensen et al., 1997; Brown et al., 1998) . The major primary advantage of this model includes production of HPV-infected human tissue outside of the natural host for antiviral testing. Disadvantages centre on the lack of natural host immunity during papilloma development. Pre-clinical models are thus restricted to rabbit, canine and bovine models, each of which has limitations with regard to antiviral testing (Brandsma, 1994; Stanley et al., 1997) . In this article we will discuss the role of the cottontail rabbit papillomavirus (CRPV) rabbit model for antiviral and immunotherapeutic testing for papillomavirus infections in immunocompetent hosts and discuss our recent experiences with this model.
Cottontail rabbit papillomavirus (CRPV)
The CRPV/rabbit system is the most versatile model for conducting antiviral, immunopotentiating and immunotherapeutic studies on papillomavirus infections (Christensen et al., 2000a; Christensen et al., 2000b; Stanley et al., 1997) and has been used extensively over the past 70 years. Dr Richard E. Shope reported the first experimental studies on CRPV infection and virus life cycle (Shope & Hurst, 1933) . Other early investigations demonstrated that CRPV could infect laboratory rabbits of various strains, as well as snowshoe rabbits and jackrabbits (Beard & Rous, 1935) . Since this time, the CRPV rabbit model has been used extensively to study virological aspects of papillomavirus infections in vivo, virus-induced carcinogenesis, immunological features of virus infection leading to host immune-mediated regression, interactions between papillomas and cocarcinogens and viral gene function (Christensen & Kreider, 1999; Kreider, 1963; Rous & Beard, 1935; Wettstein & Stevens, 1983) .
A key improvement in the versatility of the CRPV rabbit model resulted from the demonstration of the induction of skin papillomas using purified CRPV viral DNA placed onto scarified rabbit skin (Ito & Evans, 1961) . Further improvements included infection with CRPV that is retained in bacterial plasmid vectors (Nasseri et al., 1989) , infection using the viral DNA delivered by gene gun (Brandsma et al., 1991; Jeckel et al., 2003; Salmon et al., 2000) and viral DNA placed onto hyperplastic skin (Kreider et al., 1995) . Induction of viral-DNA induced skin papillomas allows for studies on viral genetics, antiviral testing and viral immunology. A further strength of the CRPV/rabbit model is that latent infections can be generated in skin sites by infection with suboptimal doses of CRPV (Amella et al., 1994) .
Antiviral testing using the CRPV/rabbit model
Current assays using the CRPV/rabbit model involve development of discrete papillomas at accessible sites for topical and/or intra-lesional treatments. Sites located on the back of the rabbit are the most convenient to prepare and treat, and the unique properties of papillomavirus infections make these choices simple to attain. Following appropriate anaesthetization of each rabbit, four to eight scarified back sites that are about 1 cm in diameter and 5-10 cm apart are prepared and the size of the papillomas at the base is limited to the area scarified (Christensen et al., 2000b; Christensen & Kreider 1999) . After scarification and application of infectious CRPV virus stock, papillomas appear as soon as 14 days with high-titre virus stock and between 21-28 days with 100-fold less virus (Christensen et al., 2000b) . The reproducibility of the infectious cycle and time-dependent predictable appearance of papillomas are important strengths of the model for testing antiviral therapies and intervention strategies.
Compounds tested in the CRPV/rabbit model
Several groups have utilized the CRPV/rabbit model to test various antiviral and immunomodulatory compounds. A listing of these studies is presented in Table 1 . In general, these treatments included both systemic, intralesional and topical treatments, with the majority of studies focused on topical application to papillomas located at convenient sites on the back of the rabbit. Quantitation of anti-papilloma effects is easily determined by obtaining volumetric measurements of the individual papillomas at weekly intervals which does not interfere with the growth rate of the papilloma or with the health and well-being of the rabbits (Christensen et al., 2000b) .
CRPV/rabbit model strength and weaknesses
Some current strengths and weaknesses of the CRPV/ rabbit model are outlined below. In particular, there are ongoing modifications to the model that address several of the weaknesses listed below and these will be discussed in further detail in a later section of the overview.
Major strengths of the model:
1. The response to various antiviral treatments including podofilox, 5FU and cidofovir mirrors the outcome obtained following clinical treatments of HPV infections of genital and laryngeal origin (Christensen et al., 2000; Kreider et al., 1992; Kreider et al., 1993) . 2. Papilloma formation occurs with predictable stages in well-defined lesions, and the life cycle and virological components of CRPV infections parallel cutaneous and genital HPV infections.
3. The genetics and host-immune responses to CRPV infections can be studied because papillomas can be induced with wild type and mutant viral DNA prepared in bacterial plasmids. 4. CRPV-induced papillomas progress to malignancy in an analogous fashion to patient infections with high-risk HPV infections. 5. Experimental infections can be created at any site where there is hair-bearing skin. The back site is a very convenient location for direct and daily monitoring and treatment of the papillomas.
Major weaknesses of the CRPV model:
1. The species restriction of the papillomaviruses prevents CRPV from being used to generate papillomas directly in laboratory rodents.
2. Rabbits are usually outbred (some inbred lines exist) and large. These features contribute to variability in response to infection and treatments and greatly increase the costs of testing antiviral compounds. 3. A long latency period is required for progression to malignant tumours. The time to malignant onset is usually from 12-16 months when infections are started with viral DNA (unpublished observations). 4. Papillomas produced from wild-type CRPV grow vigorously and become very large with extensive keratinized surfaces that make penetration of topical agents difficult and which produce lesions that are often much larger than those found in the clinical setting. 5. CRPV infections are confined to hair-bearing cutaneous sites. Most of the HPV-associated morbidity in patients occurs from infections of the mucosal epithelium. 
Recent modifications of the CRPV model
Several recent modifications in the CRPV/rabbit model have been reported that increase the versatility and utility of the model. These modifications have been aimed at overcoming some of the limitations that were discussed above.
Alternative strategies for infection
The earliest infections of rabbit skin utilized stocks of infectious CRPV extracted from papillomas found on the natural host, the cottontail rabbit (Shope & Hurst, 1933) . Laboratory rabbits were shown to be susceptible to CRPV infections but developed lesions that were virus poor and thus not a useful future source of infectious virions. This initial limitation was alleviated by developing infections with purified viral DNA, and later by viral DNA grown in bacterial plasmids. Initially, yield of papillomas was variable and required pre-treatments of skin with agents that induced hyperplasia (Kreider et al., 1995) . However, recent work in our laboratory has produced papilloma yields close to 100% by delaying the application of viral DNA for 24-96 h after scarification without the need for using pretreatments (unpublished data).
Other laboratories have used the gene gun and/or other ballistic devices to deliver the viral DNA with various levels of success from 10-100%. This variability in papilloma yield can contribute to some uncertainties when antiviral treatments are conducted on sites that have yet to develop papillomas. In these latter situations, a lack of a papilloma at the treatment site may be due to either treatment cures or to infection failures. It is likely that a combination of superficial wounding and delayed DNA delivery will maximise papilloma yield and this improved infection rate may be due to the known increased susceptibility of wounded epithelium to papillomavirus infection.
Production of latent viral infections
CRPV infections with suboptimal concentrations of virions and viral DNA can produce latent infections that are amenable to testing antiviral agents (Amella et al., 1994) and immunotherapy. Given that a significant number of HPV infections remain latent and can become clinically visible under immunosuppressive conditions, this feature of the CRPV/rabbit model is particularly useful and valid for such clinically relevant infections.
Production and infections with mutant genomes
Production of CRPV-induced papillomas from viral DNA provides a powerful tool to study the genetics of viral-host interactions in the CRPV/rabbit model. The impact of these mutations can be studied in both immune-competent rabbits and those made immunodeficient by treatment with immunosuppressive drugs (Hu et al., 2005) . Some more recent mutant genomes that have been established in our laboratory provide opportunities to improve the antiviral testing options of the model.
Slow-growing CRPV infections
As discussed above, wild-type CRPV infections produce rapidly growing, large papillomas that are much more massive than most clinical HPV infections. The heavy keratinization of these lesions also often makes topical treatments ineffective due to lack of penetration of the antiviral compounds. Some improvements in the antiviral action of some compounds can be achieved via intralesional delivery of the compounds (Christensen et al., 2000b) , although these strategies are more difficult to administer and are potentially more painful than noninvasive topical treatments. During the course of constructing and testing various mutant CRPV genomes we have developed several slow-growing strains that are more clinically relevant with respect to lesion size and therefore particularly useful for antiviral treatments. One mutant strain that we have tested was generated by mutation of the start codon of a small gene identified as E8 (Hu et al., 2002b) . Papillomas established from mutant virions (mutant E8 or mE8) grew more slowly and were much lower in height and with less keratinization than those papillomas induced with wild-type CRPV (Figures 1 and  2 ). Larger mean papilloma sizes at sites infected with 10 -3 dilution of mE8 virus were due to a higher virus titre of the mE8 versus wtCRPV viral stocks. This mutation did not prevent production of infectious virions when grown in wild cottontail rabbit skin and thus both infectious virions and viral DNA with this mutation are available for papilloma production.
Antigenic variants of CRPV
Two major strains of naturally occurring CRPV were first described by investigators at the Pasteur Institute (Salmon et al., 2000; Salmon et al., 1997) and these strains showed substantial differences in outcome following infection of laboratory rabbits. One strain produced persistent lesions that grew continuously, whereas infections with the second strain led to high frequencies of spontaneous regressions (Salmon et al., 1997) . Genetic differences between these two strains have been mapped via direct DNA sequencing (Salmon et al., 1997) and the genetic regions that are responsible for altered regression rates have been defined (Salmon et al., 2000; Hu et al., 2002a) . We have prepared a number of mutant CRPV genomes that show varying levels of spontaneous regression, thus providing us with a set of viruses that can be used to study the impact of immunomodulators for antiviral activities (Hu et al., 2002a) . We have found that the natural CRPV strain that produces persistent papillomas responds poorly to immunomodulators (Table  1) , whereas the more antigenic mutant strains have the potential to establish statistically significant responses to these same immunopotentiating agents. Many HPV infections are cleared by host immunity and strains of CPRV with varying levels of antigenicity provide excellent opportunities to assess unknown immunomodulatory agents that produce weak to moderate antiviral activities. We have confirmed that host-mediated immunity is the major mechanism that leads to the spontaneous regression of CRPV infections because papillomas produced using regressive strains of CRPV persist in rabbits immunosuppressed with cyclosporine A (Hu et al., 2005) .
Induction of mucosal papillomavirus infections in rabbits
A potential confounding feature of the CRPV/rabbit model is that this virus infects only cutaneous tissues. However, the major pathogenic HPV types infect mucosal tissues. Thus, a strain of CRPV that is capable of infecting mucosal tissues would be of substantial benefit for the CRPV/rabbit system. Viral and host factors that control the tissue tropism of papillomaviruses are currently unknown, and we do not have a mucosatropic CRPV strain to generate genital and/or laryngeal papillomas. However, there is a second rabbit papillomavirus type, rabbit oral papillomavirus (ROPV), that naturally infects oral mucosa (Parsons & Kidd, 1936) and we have shown that ROPV can be used to generate oral and genital papillomas ( , 1998) . ROPV infection of rabbit oral and genital tissues thus provides a potential pre-clinical model for antiviral testing. However, we have not utilized this model for any such testing so far. Topical treatments of oral papillomas on rabbits are more technically challenging than is the treatments of accessible cutaneous CRPV-induced papillomas.
Future considerations for the CRPV/rabbit model
Several important and recent improvements have been described for the CRPV/rabbit model. The utility of the model has been enhanced significantly by genetic modification of viral genomes that display defined endpoints following infection of both immunocompetent and immunosuppressed rabbits. Each of these viral genomes allow specific, situational testing of antiviral, immunopotentiating and immunotherapeutic agents and their various combinations in vivo. Further refinements are underway and the set of CRPV (and ROPV) reagents that are still needed for testing various types of antiviral and immunomodulatory compounds are outlined in Table 2 . In summary a "complete" set of tools for testing papilloma antiviral compounds and various combination treatments would be possible if we have rabbit papillomavirus strains that showed benign, malignant, regressive, progressive, cutaneous and mucosal-targeting properties. Some of these reagents are already available, whereas the remaining variants are under consideration. We are well aware of the difficulties in developing CRPV (and ROPV) genomes that show altered tissue targeting and such genomes may not be immediately required if both CRPV and ROPV strains are available for infection of both cutaneous and mucosal epithelium. We have not been able to generate oral papillomas from ROPV DNA at this time; CRPV, cottontail rabbit papillomavirus; ROPV, rabbit oral papillomavirus.
